FDA Approves Ensitrelvir as First Oral COVID-19 Prophylaxis

The U.S. Food and Drug Administration (FDA) has approved ensitrelvir (Xocova), an oral antiviral medication developed by Shionogi & Co, Ltd, for the post-exposure prophylaxis (PEP) of COVID-19 in adults and adolescents aged 12 years and older. This landmark approval introduces the first oral option specifically designed to prevent symptomatic COVID-19 after exposure, addressing a critical gap in preventive care against the virus. The approval follows encouraging results from clinical trials and marks a significant advancement in the fight against COVID-19. Ensitrelvir acts as a main protease inhibitor, targeting an essential enzyme required for the replication of SARS-CoV-2, the virus responsible for COVID-19.

The treatment regimen consists of a five-day course, starting with three tablets on the first day, followed by one tablet each of the subsequent four days. The FDA’s decision came ahead of the Prescription Drug User Fee Act (PDUFA) action date, reflecting the urgency and importance of effective COVID-19 prevention strategies in the ongoing public health crisis. The approval of ensitrelvir is supported by the outcomes of the Phase 3 SCORPIO-PEP trial, which demonstrated a 67% reduction in the risk of symptomatic COVID-19 infection among participants who received the medication compared to those given a placebo. Specifically, the incidence of COVID-19 was reported at 2.9% in the ensitrelvir group versus 9.0% in the placebo group.

These findings highlight the efficacy of ensitrelvir as a proactive measure for individuals exposed to COVID-19, regardless of their vaccination status or prior immunity. The broader implications of this approval extend to various settings where COVID-19 exposure is a concern, including households, nursing homes, and healthcare facilities. Ensitrelvir provides an important option for individuals seeking to protect themselves after potential exposure, thereby helping to reduce the overall burden of COVID-19. The safety profile of the drug was also favorable, with adverse events reported at similar rates in both the treatment and placebo groups, indicating a manageable risk associated with its use.

Looking forward, the introduction of ensitrelvir is expected to play a significant role in public health strategies aimed at controlling COVID-19 transmission. As the pandemic continues to evolve, the availability of effective oral prophylactic options like ensitrelvir will be crucial in mitigating the spread of the virus. Public health officials and healthcare providers will need to integrate this new treatment into their protocols to enhance prevention efforts and protect vulnerable populations.